A Rare Case of Triple-Hit Ultra-High-Risk Multiple Myeloma Harboring t(4;14), t(14;20), and Gain(1q)
Jiao Lu
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Jingjiang People's Hospital Affiliated to Yangzhou University, Jingjiang, Jiangsu, China
Search for more papers by this authorQian Wang
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Search for more papers by this authorJing Wang
Soochow Hopes Hematonosis Hospital, Suzhou, Jiangsu, China
Search for more papers by this authorZhao Zeng
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Search for more papers by this authorXiaolan Shi
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Search for more papers by this authorDandan Liu
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Search for more papers by this authorSuning Chen
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Search for more papers by this authorLingzhi Yan
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Soochow Hopes Hematonosis Hospital, Suzhou, Jiangsu, China
Search for more papers by this authorCorresponding Author
Chengcheng Fu
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Correspondence:
Chengcheng Fu ([email protected])
Jinlan Pan ([email protected])
Search for more papers by this authorCorresponding Author
Jinlan Pan
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Correspondence:
Chengcheng Fu ([email protected])
Jinlan Pan ([email protected])
Search for more papers by this authorJiao Lu
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Jingjiang People's Hospital Affiliated to Yangzhou University, Jingjiang, Jiangsu, China
Search for more papers by this authorQian Wang
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Search for more papers by this authorJing Wang
Soochow Hopes Hematonosis Hospital, Suzhou, Jiangsu, China
Search for more papers by this authorZhao Zeng
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Search for more papers by this authorXiaolan Shi
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Search for more papers by this authorDandan Liu
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Search for more papers by this authorSuning Chen
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Search for more papers by this authorLingzhi Yan
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Soochow Hopes Hematonosis Hospital, Suzhou, Jiangsu, China
Search for more papers by this authorCorresponding Author
Chengcheng Fu
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Correspondence:
Chengcheng Fu ([email protected])
Jinlan Pan ([email protected])
Search for more papers by this authorCorresponding Author
Jinlan Pan
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China
Correspondence:
Chengcheng Fu ([email protected])
Jinlan Pan ([email protected])
Search for more papers by this authorFunding: This work was supported by the Natural Science Foundation of Jiangsu Province (Grant BK20231195).
The first three authors contributed equally to the work.
Open Research
Data Availability Statement
The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.
References
- 1 G. J. Morgan, B. A. Walker, and F. E. Davies, “The Genetic Architecture of Multiple Myeloma,” Nature Reviews. Cancer 12, no. 5 (2012): 335–348.
- 2 P. Sonneveld, H. Avet-Loiseau, S. Lonial, et al., “Treatment of Multiple Myeloma With High-Risk Cytogenetics: A Consensus of the International Myeloma Working Group,” Blood 127, no. 24 (2016): 2955–2962.
- 3 S. V. Rajkumar, “Multiple Myeloma: 2022 Update on Diagnosis, Risk Stratification, and Management,” American Journal of Hematology 97, no. 8 (2022): 1086–1107.
- 4 V. Shah, A. L. Sherborne, D. C. Johnson, et al., “Predicting Ultrahigh Risk Multiple Myeloma by Molecular Profiling: An Analysis of Newly Diagnosed Transplant Eligible Myeloma XI Trial Patients,” Leukemia 34, no. 11 (2020): 3091–3096.
- 5 C. Singh, V. Panakkal, S. Sreedharanunni, et al., “Presentation and Impact of Double and Triple Hit Cytogenetics in Patients With Multiple Myeloma in the Real World,” Clinical Lymphoma, Myeloma & Leukemia 22, no. 8 (2022): e685–e690.
- 6 M. Baysal, U. Demirci, E. Umit, et al., “Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance,” Scientific Reports 10, no. 1 (2020): 5991.
- 7 M. F. Kaiser, A. Hall, K. Walker, et al., “Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma,” Journal of Clinical Oncology 41, no. 23 (2023): 3945–3955.
- 8 I. J. Cardona-Benavides, C. de Ramón, and N. C. Gutiérrez, “Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications,” Cells 10, no. 2 (2021): 336.
- 9 K. D. Boyd, F. M. Ross, L. Chiecchio, et al., “A Novel Prognostic Model in Myeloma Based on Co-Segregating Adverse FISH Lesions and the ISS: Analysis of Patients Treated in the MRC Myeloma IX Trial,” Leukemia 26, no. 2 (2012): 349–355.
- 10 S. Goldman-Mazur, A. Jurczyszyn, J. J. Castillo, et al., “Different MAF Translocations Confer Similar Prognosis in Newly Diagnosed Multiple Myeloma Patients,” Leukemia & Lymphoma 61, no. 8 (2020): 1885–1893.
- 11 S. Hao, X. Lu, Z. Gong, et al., “The Survival Impact of CKS1B Gains or Amplification Is Dependent on the Background Karyotype and TP53 Deletion Status in Patients With Myeloma,” Modern Pathology 34, no. 2 (2021): 327–335.
- 12 A. M. Poos, N. Prokoph, M. J. Przybilla, et al., “Resolving Therapy Resistance Mechanisms in Multiple Myeloma by Multiomics Subclone Analysis,” Blood 142, no. 19 (2023): 1633–1646.
